Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

131.39USD
22 Sep 2017
Change (% chg)

$-0.36 (-0.27%)
Prev Close
$131.75
Open
$131.99
Day's High
$132.39
Day's Low
$131.28
Volume
1,554,107
Avg. Vol
1,871,152
52-wk High
$137.07
52-wk Low
$109.32

Chart for

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $352,650.69
Shares Outstanding(Mil.): 2,684.00
Dividend: 0.84
Yield (%): 2.56

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

FDA declines to approve J&J arthritis drug sirukumab

The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.

Sep 22 2017

UPDATE 2-FDA declines to approve J&J arthritis drug sirukumab

Sept 22 The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.

Sep 22 2017

U.S. FDA rejects J&J's arthritis drug

Sept 22 The U.S. Food and Drug Administration has declined to approve Johnson & Johnson's rheumatoid arthritis drug sirukumab, saying additional clinical data is needed to further evaluate its safety, the company said on Friday.

Sep 22 2017

J&J unit loses bid to dismiss whistleblower's retaliation claims

A Johnson & Johnson subsidiary has lost a bid to dismiss claims that it retaliated against a former employee whose whistleblower lawsuit led to an $18 million settlement with the U.S. Justice Department.

Sep 21 2017

Pfizer files suit against J&J over Remicade contracts

Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson , saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

Sep 20 2017

UPDATE 3-Pfizer files suit against J&J over Remicade contracts

Sept 20 Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

Sep 20 2017

Pfizer files suit against J&J over Remicade contracts

Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying its rival's contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer's new biosimilar.

Sep 20 2017

Pfizer sues Johnson & Johnson over Remicade biosimilar

Sept 20 Pfizer Inc on Wednesday filed a lawsuit against Johnson & Johnson, saying that the drugmaker's anticompetitive contracts with health insurers prevented biosimilar competition to its blockbuster rheumatoid arthritis drug, Remicade.

Sep 20 2017

BRIEF-‍Pfizer files lawsuit against Johnson & Johnson​

* ‍Pfizer says filed suit in U.S. District Court for Eastern District of Pennsylvania against Johnson & Johnson​

Sep 20 2017

PhRMA urges 1st Circuit to reconsider J&J whistleblower ruling

The drug industry's largest trade group is urging a federal appeals court to reconsider a decision reviving a whistleblower lawsuit against Johnson & Johnson, saying it incorrectly relaxed standards that can protect companies from "parasitic" lawsuits.

Sep 18 2017

Earnings vs. Estimates